中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

155 records (took 0.043 seconds)

    FK-506 and rapamycin specific binding immunophilin
    31.
    发明授权
    FK-506 and rapamycin specific binding immunophilin 失效
    FK-506和雷帕霉素特异性结合免疫亲和素

    公开(公告)号：US5354845A

    公开(公告)日：1994-10-11

    申请号：US50576

    申请日：1993-04-21

    Applicant: Steven J. Soldin

    Inventor： Steven J. Soldin

    IPC: C07K14/47 ,  C07K15/00 ,  C07K15/06 ,  C07K17/02

    CPC classification number: C07K14/47 ,  Y10S436/815 ,  Y10S530/837

    Abstract: A new homogeneous cytosolic binding protein (FKBP-14.6 immunophilin) having a molecular weight of about 14.6 kDa (calculated from its amino acid composition), reversibly binds the immunosuppressive drugs FK-506, rapamycin or chemically related compounds, but not cyclosporine. The FKBP-14.6 protein has a pI of 6.5-7.5, and the (partial) N-terminal amino acid sequence: NH.sub.2 -Lys-Leu-Pro-Tyr-Glu-Leu-Lys-Xaa-Asn-Val-Lys-Ala-Phe-Xaa-Xaa-Lys-Val- (Seq. ID. No: 1) (where Xaa is undefined), and partial internal amino acid sequences -Val-Leu-Asp-Thr-Ala-Tyr-Glu-Tyr-Gly-Ala-Glu-Ala-Leu-Glu- (Seq. ID. No: 2), -Glu-Phe-Thr-Pro-Val-Phe-Gln-Ala-Xaa-Phe- (Seq. ID. No: 3) and -Ser-Leu-Val-Pro-Leu-Val-Gly-Xaa-Lys- (Seq. ID. No. 4) (where Xaa is undefined). This N-terminal amino acid sequence exhibits no homology to FKBP-12 or membrane-associated FKBP-13. The FKBP-14.6 is isolated from the cytosol of mammalian tissues, preferably calf thymus, and can be used in diagnostic and purification procedures involving FK-506 and rapamycin-type immunosuppressant drugs.

    Abstract translation: 具有约14.6kDa分子量（由其氨基酸组成计算）的新的均质胞质结合蛋白（FKBP-14.6免疫亲和素）可逆地结合免疫抑制药物FK-506，雷帕霉素或化学相关化合物而不是环孢菌素。 FKBP-14.6蛋白的pI为6.5-7.5，（部分）N-末端氨基酸序列：NH2-Lys-Leu-Pro-Tyr-Glu-Leu-Lys-Xaa-Asn-Val-Lys-Ala -Phe-Xaa-Xaa-Lys-Val-（序列号：1）（其中Xaa未定义）和部分内部氨基酸序列-Val-Leu-Asp-Thr-Ala-Tyr-Glu-Tyr- Gly-Ala-Glu-Ala-Leu-Glu-（Seq.ID.No:2），-Glu-Phe-Thr-Pro-Val-Phe-Gln-Ala-Xaa-Phe-（序列号： 3）和-Ser-Leu-Val-Pro-Leu-Val-Gly-Xaa-Lys-（Seq.ID.4号）（其中Xaa未定义）。 该N-末端氨基酸序列与FKBP-12或膜相关的FKBP-13不显示同源性。 FKBP-14.6从哺乳动物组织的细胞溶质中分离，优选小牛胸腺，并且可用于涉及FK-506和雷帕霉素型免疫抑制剂药物的诊断和纯化程序。

    Immunological methods for the detection of the human type IV collagen .alpha.5 chain
    32.
    发明授权
    Immunological methods for the detection of the human type IV collagen .alpha.5 chain 失效
    用于检测人类IV型胶原α5链的免疫学方法

    公开(公告)号：US5354690A

    公开(公告)日：1994-10-11

    申请号：US630563

    申请日：1990-12-20

    Applicant: Karl Tryggvason ,  Sirkka L. Hostikka ,  Matti Hoyhtya

    Inventor： Karl Tryggvason ,  Sirkka L. Hostikka ,  Matti Hoyhtya

    IPC: C07K14/78 ,  C12Q1/68 ,  G01N33/53 ,  C07K15/00 ,  C12Q1/00 ,  G01N33/569

    CPC classification number: C12Q1/6883 ,  C07K14/78

    Abstract: The present invention provides for a method for preparing antibodies that specifically detect the type IV collagen .alpha.5 chain that is defective in various basement membrane disorders such as in X chromosome-linked Alport's syndrome. The invention further provides for the use of such antibodies to detect the .alpha.5(IV) collagen chain in solutions and other human tissue specimens using immunological methods comprised of antibodies specific for said protein. Along this line, the invention relates to the use of the specific antibodies to examine the presence or absence of the .alpha.5(IV) collagen chain in the tissues, e.g. skin or kidneys, etc. of patients with renal failure, possibly due to Alport's syndrome.

    Abstract translation: 本发明提供了一种制备抗体的方法，所述抗体特异性检测了各种基底膜病症如X染色体连锁的阿尔波特综合征中有缺陷的IV型胶原α5链。 本发明进一步提供了使用这种抗体以使用由所述蛋白质特异性抗体组成的免疫学方法来检测溶液和其它人体组织标本中的α5（IV）胶原链。 沿着这条线，本发明涉及特异性抗体用于检查组织中α5（IV）胶原链的存在或不存在的情况，例如， 肾衰竭患者的皮肤或肾脏等，可能是由于阿尔波特综合症。

    75 Kilodalton interleukin-2 receptor proteins and their uses
    33.
    发明授权
    75 Kilodalton interleukin-2 receptor proteins and their uses 失效
    75基洛尔顿白介素-2受体蛋白及其用途

    公开(公告)号：US5352772A

    公开(公告)日：1994-10-04

    申请号：US944337

    申请日：1986-12-19

    Applicant: Kendall A. Smith

    Inventor： Kendall A. Smith

    IPC: A61K38/00 ,  C07K14/715 ,  C07K15/00

    CPC classification number: C07K14/7155 ,  A61K38/00 ,  Y10S530/808 ,  Y10S530/81 ,  Y10S530/811 ,  Y10S530/812 ,  Y10S530/82

    Abstract: A new cellular protein produced by activated T cells and involved in the high affinity binding of interleukin-2 has been discovered. This protein has a molecular weight of about 75,000 (Mr) and is further characterized as having an affinity for IL-2 (in the absence of other receptor proteins) of about 10.sup.-9 molar and is substantially unreactive with anti-Tac antibodies. This new cellular protein, referred to herein as the ".alpha. chain," is believed to interact with the previously isolated 55,000 dalton receptor protein (referred to herein as the ".beta. chain") to form the high affinity interleukin-2 receptor which triggers the growth and mitosis of T cells during an immune response. Methods for isolating and purifying the .alpha. chain protein are disclosed herein as well as techniques for cloning and expressing the protein and related materials. Techniques for raising monoclonal antibodies to such proteins are also disclosed. Diagnostic and therapeutic uses for the novel receptor protein (or particular epitopes thereof) as well as monoclonal antibodies (or active fragments) reactive therewith are proposed.

    Abstract translation: 已经发现由活化的T细胞产生并参与白细胞介素-2的高亲和力结合的新的细胞蛋白质。 该蛋白质具有约75,000（Mr）的分子量，并进一步表征为对约10-9摩尔的IL-2（不存在其它受体蛋白）具有亲和性，并且与抗Tac抗体基本上不反应。 这种新的细胞蛋白（本文中称为“α链”）被认为与先前分离的55,000道尔顿受体蛋白（本文称为“β链”）相互作用以形成高亲和力的白细胞介素-2受体，其触发 在免疫应答期间T细胞的生长和有丝分裂。 本文公开了分离和纯化α链蛋白的方法以及用于克隆和表达蛋白质和相关材料的技术。 还公开了提高这种蛋白质的单克隆抗体的技术。 提出了新型受体蛋白（或其特定表位）的诊断和治疗用途以及与其反应的单克隆抗体（或活性片段）。

    Antigen specifically expressed on the surface of B cells and Hodgkin's cells
    36.
    发明授权
    Antigen specifically expressed on the surface of B cells and Hodgkin's cells 失效
    抗原特异性表达于B细胞和霍奇金细胞表面

    公开(公告)号：US5304635A

    公开(公告)日：1994-04-19

    申请号：US994082

    申请日：1992-12-16

    Applicant: Ashraf Imam ,  Clive R. Taylor

    Inventor： Ashraf Imam ,  Clive R. Taylor

    IPC: C07K14/705 ,  C07K16/28 ,  C07K16/30 ,  C07K15/00 ,  A61K35/14

    CPC classification number: C07K14/705 ,  C07K16/28 ,  C07K16/3061 ,  C07K2317/73 ,  Y10S530/837

    Abstract: The invention relates to a new antigen termed BLA-35 specifically expressed on the surface of Hodgkin's cells, Reed-Sternberg cells and B lymphocytes, and to a new monoclonal antibody (anti-BLA-36) specific thereto. The antigen is characterized by the following properties:a molecular weight of about 36,000 D;the presence of an epitope recognized by antibody to said protein;specific expression by Hodgkin's cells and Reed-Sternberg cells in all subsets of Hodgkin's disease, and by activated and early proliferating B cells;no expression by T cells;capability of reacting with its antibody in both frozen and fixed/paraffin embedded tissues;a function associated with the growth of cells capable to express said antigen protein.

    Abstract translation: 本发明涉及在霍奇金细胞，Reed-Sternberg细胞和B淋巴细胞表面特异性表达的称为BLA-35的新抗原，以及与其特异性的新的单克隆抗体（抗BLA-36）。 抗原的特征在于以下性质：分子量约36,000D; 存在抗体对所述蛋白质识别的表位; Hodgkin's细胞和Reed-Sternberg细胞在霍奇金病的所有亚型中的特异性表达，以及活化和早期增殖的B细胞; T细胞无表达; 在冷冻和固定/石蜡包埋组织中与其抗体反应的能力; 与能够表达所述抗原蛋白的细胞的生长相关的功能。

    Monoclonal antibodies directed against complexes formed by thrombin and hirudin
    37.
    发明授权
    Monoclonal antibodies directed against complexes formed by thrombin and hirudin 失效
    针对由凝血酶和水蛭素形成的复合物的单克隆抗体

    公开(公告)号：US5296352A

    公开(公告)日：1994-03-22

    申请号：US763860

    申请日：1991-09-23

    Applicant: Jean-Marc Schlaeppi

    Inventor： Jean-Marc Schlaeppi

    IPC: C12N5/10 ,  C07K16/36 ,  C07K16/38 ,  C07K16/44 ,  C12N15/02 ,  C12P21/08 ,  C12R1/91 ,  G01N33/53 ,  G01N33/577 ,  A61K35/14 ,  C07K15/00

    CPC classification number: C07K16/38 ,  C07K16/36

    Abstract: The invention concerns monoclonal antibodies which are directed against the thrombin/hirudin-complex and derivatives thereof, processes for their preparation, hybridoma cell lines secreting said monoclonal antibodies, and processes for the preparation of the hybridoma cell lines. Furthermore, the invention relates to the use of the monoclonal antibodies and/or their derivatives for the determination of the thrombin/hirudin-complex as well as to test kits comprising said monoclonal antibodies and/or their derivatives.

    Abstract translation: 本发明涉及针对凝血酶/水蛭素 - 复合物及其衍生物，其制备方法，分泌所述单克隆抗体的杂交瘤细胞系以及杂交瘤细胞系的制备方法的单克隆抗体。 此外，本发明涉及单克隆抗体和/或其衍生物用于测定凝血酶/水蛭素 - 复合物以及测试包含所述单克隆抗体和/或其衍生物的试剂盒的用途。

    Polyamino acid superabsorbents
    38.
    发明授权
    Polyamino acid superabsorbents 失效
    聚氨基酸超吸收剂

    公开(公告)号：US5284936A

    公开(公告)日：1994-02-08

    申请号：US870241

    申请日：1992-04-17

    Applicant: Julie Donachy ,  C. Steven Sikes

    Inventor： Julie Donachy ,  C. Steven Sikes

    IPC: A61L15/00 ,  A61F13/53 ,  A61L15/60 ,  B01J20/22 ,  C07K2/00 ,  C07K14/00 ,  C08G69/10 ,  C08G73/10 ,  C09K3/00 ,  A61F13/15 ,  B01J20/26 ,  C07K15/00 ,  C08L77/04

    CPC classification number: C08G73/1092 ,  A61L15/60 ,  C07K14/001 ,  C08G69/10

    Abstract: Substantially water-insoluble, crosslinked polypeptides containing 15 to 85 mole % of amino acid residues such as glutamic acid, aspartic acid, phosphoserine, phosphohomoserine, phosphotyrosine, phosphothreonine, phosphoasparagine, or phosphoglutamine, and 15 to 85 mole % of amino acid residues such as lysine, arginine, asparagine, glutamine, serine or tyrosine, in which the degree of crosslinking is sufficient to result in a substantially water-insoluble polypeptide with the ability to absorb a 1 wt. % aqueous NaCl solution in an amount of at least 20 times the weight of the polypeptide, are useful as superabsorbents in devices such as diapers, etc. Mild alkaline hydrolysis of the crosslinked polypeptides increases their superabsorbency by two to three fold.

    Abstract translation: 含有15〜85摩尔％的氨基酸残基例如谷氨酸，天冬氨酸，磷酸丝氨酸，磷酸高丝氨酸，磷酸酪氨酸，磷酸苏氨酸，磷酸磷酸谷氨酰胺或磷酸谷氨酰胺的基本上不溶于水的交联的多肽，以及15〜85摩尔％的氨基酸残基例如 赖氨酸，精氨酸，天冬酰胺，谷氨酰胺，丝氨酸或酪氨酸，其中交联度足以导致基本上不溶于水的多肽，其具有吸收1重量％ 数量为多肽重量的20倍的NaCl水溶液，可用作尿布等装置中的超吸收剂。交联的多肽的轻度碱性水解将其超吸收性增加2至3倍。

Patent Agency Ranking